Educational comparison of published peer-reviewed weight-loss data. Cross-trial comparisons are directional only — trial designs differ in titration speed, duration, and patient population. Not clinical guidance or treatment recommendation. Retatrutide is investigational; consult a licensed clinician for any treatment decision.
The Three Drugs at a Glance
Semaglutide, tirzepatide, and retatrutide form a clean three-step ladder of incretin pharmacology. Each adds one receptor pathway to the previous, and each step has produced a measurable jump in weight-loss magnitude in pivotal trials.
| Attribute | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Brand | Wegovy, Ozempic, Rybelsus | Zepbound, Mounjaro | Investigational (LY3437943) |
| Mechanism | GLP-1 mono-agonist | GLP-1 + GIP dual agonist | GLP-1 + GIP + glucagon triple agonist |
| Mean weight loss | −14.9 % @ 68 wk | −22.5 % @ 72 wk | −24.2 % @ 48 wk |
| Pivotal trial | STEP-1 (Wilding 2021) | SURMOUNT-1 (Jastreboff 2022) | Phase 2 (Jastreboff 2023) |
| Dose at endpoint | 2.4 mg weekly SC | 15 mg weekly SC | 12 mg weekly SC |
| Half-life | ~7 days | ~5 days | ~6 days |
| Regulatory | FDA-approved (obesity + T2D) | FDA-approved (obesity + T2D) | Investigational, Phase 3 ongoing |
How They Work: One, Two, Three Receptors
Semaglutide activates a single receptor — GLP-1R — found in pancreatic beta cells, the hindbrain, and the gut. The result is glucose-dependent insulin secretion, slowed gastric emptying, and centrally-mediated appetite suppression. This is the foundational incretin pathway, and the basis on which all subsequent obesity-pharmacology designs have built.
Tirzepatide adds the GIP receptor (GIPR), expressed on beta cells and abundant in white adipose tissue. GIP co-activation amplifies postprandial insulin secretion and adds an insulin-sensitization arm; clinical evidence suggests it also enhances satiety synergistically with GLP-1R. Tirzepatide's potency is GIPR-skewed — it activates GIPR more strongly than GLP-1R — which is one reason the receptor profile is not simply additive with semaglutide.
Retatrutide adds glucagon receptor (GCGR) activation to GLP-1R and GIPR. GCGR's role is energy expenditure: chronic, controlled activation raises basal metabolic rate and accelerates hepatic fatty acid oxidation. The historical concern with glucagon activation — hyperglycemia — is offset in the triple-agonist context by simultaneous GLP-1R/GIPR co-activation, which drives glucose-dependent insulin release and improves peripheral insulin sensitivity. The result is net catabolic effects without sustained glucose excursions. Retatrutide is also engineered for balanced potency across all three receptors, in contrast to tirzepatide's GIPR-skew. For the receptor-level deep dive, see retatrutide receptor binding mechanism.
Pivotal Trial Outcomes
Semaglutide — STEP-1 (Wilding et al., NEJM 2021)
STEP-1 randomized 1,961 adults with obesity (without diabetes) to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. The semaglutide group achieved a mean body-weight reduction of −14.9 % versus −2.4 % for placebo (treatment difference −12.4 percentage points). The largest single-class outcome trial for a GLP-1 mono-agonist in obesity, STEP-1 was the regulatory basis for the Wegovy approval. PMID 33567185.
Tirzepatide — SURMOUNT-1 (Jastreboff et al., NEJM 2022)
SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) to once-weekly tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks. The 15 mg arm achieved −22.5 % mean weight loss (treatment difference −17.8 vs placebo). The dose-response was clean — 5 mg −16.0 %, 10 mg −21.4 %, 15 mg −22.5 % — with no plateau at the highest dose. PMID 35658024.
Retatrutide — Phase 2 obesity (Jastreboff et al., NEJM 2023)
The Phase 2 obesity trial randomized 338 adults with obesity (without diabetes) to once-weekly retatrutide (1, 4, 8, or 12 mg) or placebo for 48 weeks. The 12 mg arm achieved −24.2 % mean weight loss versus −2.1 % for placebo. The dose-response did not plateau through 12 mg — 1 mg −8.7 %, 4 mg −17.1 %, 8 mg −22.8 %, 12 mg −24.2 % — and proportion achieving ≥15 % weight loss reached 83 % at the top dose. PMID 37366315. The retatrutide Phase 2 T2D trial in parallel produced 2.02-point HbA1c reductions and comparable weight loss in people with type 2 diabetes. PMID 37385280.
Caveats on Cross-Trial Ranking
Direct head-to-head trials between these three drugs in obesity populations are limited. The numbers above come from separate trials with different durations (48 vs 68 vs 72 weeks), different titration schedules, different inclusion criteria, and different placebo response rates. A few caveats worth keeping in front of mind:
- Duration matters. Both semaglutide and tirzepatide weight-loss curves continue to descend past 48 weeks. Retatrutide's 48-week endpoint may underestimate its eventual plateau magnitude relative to semaglutide's 68-week and tirzepatide's 72-week readouts.
- Phase 2 vs Phase 3. Retatrutide's pivotal data are still Phase 2 (n=338). Phase 3 efficacy in larger, more diverse populations can shift means by several percentage points in either direction.
- Population differences. Trials enrolled different baseline BMIs, comorbidity profiles, and prior weight-loss-medication exposures. Higher baseline BMI generally yields larger percentage weight loss across the class.
- Titration speed influences tolerability + adherence. Slower titration improves GI tolerability and may modestly improve final-endpoint weight loss.
Until head-to-head Phase 3 trials report at matched durations, the cleanest read is: more receptors, more weight loss — directionally — with the caveat that magnitude differences between tirzepatide and retatrutide at 12+ months may be smaller than 48-week vs 72-week cross-trial data suggest.
Side Effects and Tolerability
All three share the same dose-dependent gastrointestinal profile driven by GLP-1R activation: nausea (most common, typically transient during titration), vomiting, diarrhea, constipation, and dyspepsia. Severity correlates with dose and titration speed. Discontinuation rates due to GI adverse events ranged 4-7 % in STEP-1, SURMOUNT-1, and retatrutide Phase 2 — broadly comparable across the class.
Class-level safety considerations include rare but serious risks: pancreatitis, gallbladder events (cholelithiasis, cholecystitis), and the medullary thyroid carcinoma boxed warning that applies across the GLP-1 receptor agonist class based on rodent data. Long-term cardiovascular safety is established for semaglutide (SELECT trial) and emerging for tirzepatide; retatrutide's long-term outcomes await Phase 3.
The specific concern unique to retatrutide — sustained glucagon receptor activation — did not produce clinically relevant hyperglycemia in Phase 2 trials of either obesity or type 2 diabetes populations. The insulinotropic GLP-1 and GIP arms appear to compensate at therapeutic doses.
Access, Cost, and Real-World Choice
Semaglutide and tirzepatide are FDA-approved and broadly available through retail and telehealth pharmacy channels, with insurance coverage variable by plan. Both have brand-name (Wegovy/Ozempic, Zepbound/Mounjaro) and generic/compounded pathways subject to FDA shortage-status rules. Cash-pay coupon programs from manufacturers shift the effective monthly cost.
Retatrutide is investigational and not commercially available through any approved pharmacy channel. Phase 3 enrollment may offer access for eligible participants; the TRIUMPH program is ongoing as of 2026. For research-context information, see the retatrutide clinical trials overview.
Which One? Framing the Choice
For an FDA-approved option today, the practical choice is between semaglutide and tirzepatide. SURMOUNT-1 versus STEP-1 cross-trial data favor tirzepatide for weight-loss magnitude, but individual response, tolerability, comorbidity profile, prior medication history, insurance coverage, and clinician judgment all factor in. The forthcoming SURMOUNT-5 head-to-head data (semaglutide vs tirzepatide in obesity at matched duration) will sharpen this comparison considerably.
For a person tracking the pipeline, retatrutide represents the next anticipated step. Approval timing depends on Phase 3 readouts and FDA review; nothing about Phase 2 data should be taken as a guarantee of Phase 3 results.
For a deeper look at any single comparison, see semaglutide vs tirzepatide, semaglutide vs retatrutide, or tirzepatide vs retatrutide. For mechanism context, see retatrutide mechanism of action. For the broader peptide landscape, see how weight-loss peptides compare.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID 33567185. (STEP-1)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID 35658024. (SURMOUNT-1)
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID 35985340.
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315.
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial. Lancet. 2023;402(10401):529-544. PMID 37385280.
This page summarizes published peer-reviewed research for educational purposes. It is not medical advice. Retatrutide is an investigational drug not FDA-approved for any indication. Semaglutide and tirzepatide are FDA-approved but require physician evaluation for appropriateness. Always consult a licensed clinician before considering any treatment.